Signos, a digital health company focused on glucose-informed weight management, has secured $20 million in funding from Dexcom, GV (Google Ventures) and Blue Cross Blue Shield of Alabama. The financing round coincides with a new commercial partnership with Dexcom that will make Signos available through Dexcom’s direct-to-consumer Stelo platform.
Founded in 2018 and based in California, Signos provides an FDA-cleared mobile application that integrates over-the-counter continuous glucose monitoring data with artificial intelligence-driven analytics. The system is designed to help users better understand how diet, exercise, sleep, and other lifestyle behaviors affect metabolic health and weight management outcomes.
Under the agreement, glucose data captured through Dexcom’s Stelo continuous glucose monitoring system will be processed through the Signos platform to generate personalized metabolic insights. The company said the technology identifies how specific foods and behaviors influence glucose fluctuations and can also help users detect high and low glucose levels.
The investment will support Signos’ next phase of growth as consumer adoption of continuous glucose monitoring expands beyond diabetes management into broader wellness and preventive health applications.
“Signos has developed a system that translates glucose biosensing data into actionable insights for people focused on weight management,” Jon Coleman, chief commercial officer at Dexcom, said in a statement.
“Making Signos available on Stelo.com is a natural next step. It makes a powerful, FDA-cleared technology even more accessible for people who are already looking for smarter ways to manage their weight and health.”
The partnership adds to Dexcom’s broader strategy of investing in digital health, biosensing, and connected health technologies through Dexcom Ventures, which launched in 2021. The company has backed multiple healthcare and medical technology firms spanning wearable monitoring, insulin delivery, cybersecurity, and remote patient monitoring.
Among Dexcom’s recent investments was a $75 million strategic investment in Oura in 2024, accompanied by a partnership enabling two-way data integration between Dexcom continuous glucose monitors and the Oura Ring. Oura later raised an additional $900 million and confidentially filed for an initial public offering with the U.S. Securities and Exchange Commission earlier this month.
Dexcom Ventures has also invested in Nutromics, Medcrypt, Epitel, BioIntelliSense, and Beta Bionics as part of its expanding digital health portfolio.
Click here for the original news story.
